Direct Answer
42 SEC filers are classified under the Standard Industrial Classification codes that describe the life sciences tools industry, and their latest annual reports show $93.9 billion of combined revenue and a median operating margin of -5.5%. Investors should still evaluate its revenue model, industry-specific KPIs, valuation framework and the risks that can change the group's economics.
Industry Overview
Life sciences tools companies supply instruments, reagents and services used in drug discovery, bioprocessing and diagnostics. Consumables drive recurring revenue, and funding conditions shape orders. The first numbers to compare across companies here are organic growth, consumables share and book-to-bill.
Key Industry Metrics
- Organic growth: Sales growth excluding acquisitions and currency effects. It follows research funding and bioprocessing activity, and can swing when customers reduce inventory.
- Consumables share: Portion of revenue from reagents and supplies reordered with use. A higher share creates recurring income less tied to capital budgets.
- Book-to-bill: New orders divided by revenue recognized in a period. A reading above one signals orders exceeding shipments and future growth, while below one points to slowing demand.
- Gross and operating margin: Share of sales left after production cost, and after operating expenses too. Together they show the effect of mix and scale versus spending on research and selling.
- End-market mix: Split of sales among biopharma, academic, clinical and industrial customers. It shows exposure to different funding cycles.
Primary Macro Drivers
- Biopharma research and development spending: Drug developers buy instruments and consumables from research budgets, so spending moves organic growth and book-to-bill.
- Academic funding: Universities buy through grants, so changes in public funding affect orders in the academic end-market.
- Bioprocessing capacity: More biologic production means more filters, resins and bags are used per batch, so capacity growth supports consumables.
- Technology adoption: New techniques in sequencing and cell analysis create product cycles, which support orders and replacement of older instruments.
Major Risks
- Funding downturns: When funding tightens in biotech and academia, orders fall quickly; watch book-to-bill and end-market mix.
- Customer destocking: Customers that built up stock stop reordering until it is used, so sales fall below true demand; watch customer inventory commentary.
- Competition: Rivals compete on price and features, which can narrow margins; watch gross margin and win rates.
- Currency: Sales across many countries are translated into the reporting currency, so currency moves change reported growth; watch organic versus reported growth.
Industry Characteristics
| Characteristic | Profile |
|---|---|
| Cyclicality | Mixed |
| Capital Intensity | Medium |
| Regulatory Intensity | Medium |
| Industry Maturity | Growth |
| Geographic Importance | Global |
Life Sciences Tools Filers in the SEC Record
42 companies with annual reports in the dataset are classified by the SEC in the Standard Industrial Classification codes 3826, 3823, 8731. Their latest fiscal years end between 2025 and 2026, and together they reported $93.9 billion of revenue. Median revenue growth over the prior year was 2.7%. Median operating margin was -5.5% and median net margin -2.6%. Median total liabilities were 40% of total assets, and 18 of 42 reported a profit in their latest year.
| Company | Revenue | Growth | Operating margin | Net margin | Year |
|---|---|---|---|---|---|
| Iqvia Holdings Inc. | $16.3 billion | 5.9% | 13.4% | 8.3% | FY 2025 |
| Roper Technologies Inc | $7.9 billion | 12.3% | 28.3% | 19.4% | FY 2025 |
| Ametek Inc/ | $7.4 billion | 6.6% | 25.8% | 20.0% | FY 2025 |
| Agilent Technologies, Inc. | $6.9 billion | 6.7% | 21.3% | 18.8% | FY 2025 |
| Avantor, Inc. | $6.6 billion | -3.4% | -3.8% | -8.1% | FY 2025 |
| Keysight Technologies, Inc. | $5.4 billion | 8.0% | 16.3% | 15.8% | FY 2025 |
| Incyte Corp | $5.1 billion | 21.2% | 29.5% | 25.0% | FY 2025 |
| Illumina, Inc. | $4.3 billion | -0.7% | 18.6% | 19.6% | FY 2025 |
The 8 largest of 42 by revenue. Source: each company's own annual report as filed with the SEC (XBRL data), figures in U.S. dollars. A company's SIC code reflects its main business as the SEC records it, so it can differ from how an index provider or analyst classifies the company, and a diversified group appears under only one code.
Where to Go Next
The Life Sciences Tools guide describes how the industry earns money, what to measure and what can go wrong. To see how it compares, read the neighbouring industries in the same sector, then apply the same checks to a specific company.
More in Health Care
- Health Care sector overview
- Life Sciences Tools & Services
- Large-Cap Pharmaceuticals
- Managed Care
- Large-Cap Biotechnology
- Managed Health Care
- Laboratory Instruments
- Medicaid Managed Care
- Infection Prevention Products
Put it to work
Frequently Asked Questions
What are the main KPIs for the Life Sciences Tools industry?
Key performance indicators for the Life Sciences Tools industry include: Organic growth, Consumables share, Book-to-bill, Gross and operating margin, End-market mix. Which matter most depends on the company's model, so compare them across several companies rather than relying on one.
How cyclical is the Life Sciences Tools industry?
The Life Sciences Tools industry exhibits mixed cyclicality characteristics. Some segments move with the broader economy while others maintain more stable demand, making stock selection within the group particularly important.
What are the biggest risks in the Life Sciences Tools industry?
The primary risks for Life Sciences Tools companies include: Funding downturns, Customer destocking, Competition, Currency. Investors should assess each company's exposure to these factors and its track record of navigating them.